TimesSquare Capital Management LLC Has $61.22 Million Stock Holdings in Insmed, Inc. $INSM

TimesSquare Capital Management LLC decreased its stake in Insmed, Inc. (NASDAQ:INSM) by 51.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 425,085 shares of the biopharmaceutical company’s stock after selling 448,406 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Insmed were worth $61,216,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Stone House Investment Management LLC bought a new position in Insmed in the third quarter valued at approximately $29,000. SBI Securities Co. Ltd. boosted its holdings in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 81 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Insmed during the second quarter worth $33,000. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 151 shares during the last quarter.

Insmed Price Performance

Insmed stock opened at $148.75 on Friday. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The stock’s 50 day moving average is $169.05 and its 200-day moving average is $161.89. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $31.72 billion, a price-to-earnings ratio of -24.03 and a beta of 1.11.

Insider Transactions at Insmed

In other Insmed news, CFO Sara Bonstein sold 748 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $116,942.32. Following the transaction, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO William Lewis sold 13,396 shares of Insmed stock in a transaction on Monday, February 9th. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84. Following the sale, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at $44,512,131.15. This represents a 4.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 248,253 shares of company stock valued at $44,322,342. Company insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. UBS Group decreased their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Jefferies Financial Group set a $269.00 target price on shares of Insmed in a research note on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Thursday, January 22nd. Leerink Partners restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Finally, Guggenheim reduced their target price on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $204.24.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.